Jardiance (empagliflozin) is a small molecule pharmaceutical. Empagliflozin was first approved as Jardiance on 2014-05-22. It is used to treat type 2 diabetes mellitus in the USA. It has been approved in Europe to treat type 2 diabetes mellitus. The pharmaceutical is active against sodium/glucose cotransporter 2. In addition, it is known to target sodium/glucose cotransporter 1. Jardiance's patents are valid until 2034-06-11 (FDA).
|Indication||type 2 diabetes mellitus|
|Drug Class||Phlorozin derivatives, phenolic glycosides|